ライソエンザイムM陽性モノサイトは,アンジオテンシンII誘発性動脈高血圧と血管機能障害を媒介する
Philip Wenzel1, Maike Knorr, Sabine Kossmann
12(nd) Medical Clinic, University Medical Center Mainz, Germany. wenzelp@uni-mainz.de
Circulation
|August 31, 2011
まとめ
中性粒子がなく,浸透したモノサイトとマクロファージは,アニオテンシンII誘発性高血圧と血管機能障害の主要な原動力である. これらの細胞を枯渇させると,血圧と酸化ストレスが低下し,その治療的可能性が浮き彫りにされる.
科学分野:
- 心血管生物学 心血管生物学
- 免疫学 免疫学とは
- 高血圧の研究 高血圧の研究
背景:
- アンジオテンシンII (ATII) は,高血圧と血管炎症に関連した血管収縮剤です.
- ATII誘発性高血圧における異なるミエロモノサイト細胞とNADPH酸化酵素源の特定の役割は不明である.
研究 の 目的:
- 血管新生II誘発性高血圧におけるミエロモノサイト細胞の役割を定義する.
- アンジオテンシンII媒介の血管機能不全における活性酸素種の主な源を決定する.
主な方法:
- 誘導性ディフテリア毒素受容体マウス (LysM(iDTR)) を用いて,リソ酵素M陽性 (LysM(+)) ミエロモノサイト細胞を選択的に枯渇させました.
- 高血圧を誘発するためにアニオテンシンIIを投与し,血圧,血管機能,酸化ストレスを評価した.
- フローサイトメトリー,放射線テレメトリー,大動脈環の研究,化学発光,ウエスタン・ブロッティングを用いて,細胞浸透,血圧,血管応答,NADPH酸化酵素発現を分析した.
主要な成果:
- アンジオテンシンIIは,マウスの大動脈で循環する単細胞と中性粒子を増加させた.
- LysM(+) 細胞の選択的な枯渇は単細胞の浸透を減少させ,アンジオテンシンII誘発性高血圧と血管機能不全を弱めた.
- LysM(+) 細胞の枯渇は,血管のスーパーオキシド形成とNADPHオキシダースサブユニット発現を減少させました.
結論:
- 炎症性フェノタイプを特徴とする浸透したモノサイトとマクロファージは,アニオテンシンII誘発の血管機能不全と動脈高血圧に不可欠です.
- 中性粒子は,この過程において重要な役割を果たさない.
- これらの特定のモノサイト/マクロファージ集団をターゲットにすることで,高血圧の治療戦略を提供することができる.
関連する概念動画
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

